UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTERESTS AND SHAREHOLDERS' EQUITY - USD ($) $ in Millions	Total	Total Shareholders' Equity Attributable to Bruker Corporation	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss), Net of tax	Noncontrolling Interests in Consolidated Subsidiaries	Redeemable Noncontrolling Interests
Balance at beginning of period at Dec. 31, 2023	$ 1,394.6	$ 1,377.2	$ 1.7	$ (1,237.2)	$ 282.9	$ 2,323.8	$ 6.0	$ 17.4	$ 18.7
Balance (in shares) at Dec. 31, 2023			145,164,826
Balance Treasury Shares at Dec. 31, 2023				30,778,879
Increase (Decrease) in Stockholders' Equity
Stock options exercised	3.4	3.4			3.4
Stock options exercised (in shares)			146,765
Restricted Stock units vested (in shares)			23,051
Stock based compensation	4.6	4.6			4.6
Employee stock purchase plan	0.2	0.2			0.2
Cash dividends paid to common shareholders	(7.3)	(7.3)				(7.3)
Loans to noncontrolling interest	(0.9)							(0.9)
Consolidated net income (loss)	52.3	50.9				50.9		1.4	(0.3)
Other comprehensive loss	(14.0)	(13.7)					(13.7)	(0.3)	(0.5)
Balance at end of period at Mar. 31, 2024	1,432.9	1,415.3	$ 1.7	$ (1,237.2)	291.1	2,367.4	(7.7)	17.6	17.9
Balance ending (in shares) at Mar. 31, 2024			145,334,642
Balance Treasury Shares at Mar. 31, 2024				30,778,879
Balance at beginning of period at Dec. 31, 2024	1,797.1	1,781.2	$ 1.8	$ (1,237.2)	713.4	2,406.7	(103.5)	15.9	18.1
Balance (in shares) at Dec. 31, 2024			151,677,952
Balance Treasury Shares at Dec. 31, 2024				30,778,879
Increase (Decrease) in Stockholders' Equity
Stock options exercised	0.4	0.4			0.4
Stock options exercised (in shares)			18,771
Restricted Stock units vested (in shares)			24,999
Stock based compensation	5.2	5.2			5.2
Employee stock purchase plan	0.4	0.4			0.4
Shares Repurchased	(10.1)	(10.1)		$ (10.0)	(0.1)
Shares Repurchased (in shares)			(200,731)	200,731
Cash dividends paid to common shareholders	(7.7)	(7.7)				(7.7)
Proceeds from the sale of (distributions to) noncontrolling interests, net	(0.5)							(0.5)
Consolidated net income (loss)	17.1	17.4				17.4		(0.3)	(0.4)
Other comprehensive loss	31.0	30.4					30.4	0.6	0.6
Balance at end of period at Mar. 31, 2025	$ 1,832.9	$ 1,817.2	$ 1.8	$ (1,247.2)	$ 719.3	$ 2,416.4	$ (73.1)	$ 15.7	$ 18.3
Balance ending (in shares) at Mar. 31, 2025			151,520,991
Balance Treasury Shares at Mar. 31, 2025	30,979,610			30,979,610